natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
![Natera logo](/files/LOGO/1604821-NTRA.png)
Company profile
Ticker
NTRA
Exchange
Website
CEO
Stephen Chapman
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Quest Diagnostics • Labcorp • Fortrea • Radnet • Akumin • Burning Rock Biotech • Guardant Health • Exact Sciences • Genomic Health • Invitae ...
SEC CIK
NTRA stock data
Latest filings (excl ownership)
8-K
Other Events
19 Jul 24
S-8
Registration of securities for employees
15 Jul 24
8-K
Departure of Directors or Certain Officers
18 Jun 24
DEFA14A
Additional proxy soliciting materials
5 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Natera Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
S-8
Registration of securities for employees
29 Feb 24
Transcripts
NTRA
Earnings call transcript
2024 Q1
9 May 24
NTRA
Earnings call transcript
2023 Q4
28 Feb 24
NTRA
Earnings call transcript
2023 Q3
8 Nov 23
NTRA
Earnings call transcript
2023 Q2
3 Aug 23
NTRA
Earnings call transcript
2023 Q2
3 Aug 23
NTRA
Earnings call transcript
2023 Q1
9 May 23
NTRA
Earnings call transcript
2022 Q4
28 Feb 23
NTRA
Earnings call transcript
2022 Q3
8 Nov 22
NTRA
Earnings call transcript
2022 Q2
6 Aug 22
NTRA
Earnings call transcript
2022 Q1
8 May 22
Latest ownership filings
144
Notice of proposed sale of securities
26 Jul 24
144
Notice of proposed sale of securities
24 Jul 24
4
Michael Burkes Brophy
23 Jul 24
4
Solomon Moshkevich
23 Jul 24
4
John Fesko
23 Jul 24
4
Steven Leonard Chapman
23 Jul 24
4
Jonathan Sheena
23 Jul 24
4
DANIEL RABINOWITZ
23 Jul 24
4
Steven Leonard Chapman
17 Jul 24
144
Notice of proposed sale of securities
15 Jul 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 813.82 mm | 813.82 mm | 813.82 mm | 813.82 mm | 813.82 mm | 813.82 mm |
Cash burn (monthly) | (no burn) | (no burn) | 24.77 mm | 31.85 mm | (no burn) | 11.57 mm |
Cash used (since last report) | n/a | n/a | 95.79 mm | 123.18 mm | n/a | 44.74 mm |
Cash remaining | n/a | n/a | 718.03 mm | 690.64 mm | n/a | 769.08 mm |
Runway (months of cash) | n/a | n/a | 29.0 | 21.7 | n/a | 66.5 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 402 |
Opened positions | 179 |
Closed positions | 35 |
Increased positions | 93 |
Reduced positions | 99 |
13F shares | Current |
---|---|
Total value | 10.01 tn |
Total shares | 125.16 mm |
Total puts | 262.50 k |
Total calls | 249.00 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 11.04 mm | $1.01 tn |
Alger Associates | 8.97 mm | $0.00 |
JPM JPMorgan Chase & Co. | 7.36 mm | $672.96 bn |
Fred Alger Management | 6.55 mm | $598.78 bn |
BLK Blackrock | 6.49 mm | $593.20 bn |
Farallon Capital Management | 3.93 mm | $359.23 bn |
AMP Ameriprise Financial | 3.44 mm | $314.80 bn |
IVZ Invesco | 3.21 mm | $293.60 bn |
STT State Street | 2.72 mm | $249.04 bn |
Millennium Management | 2.64 mm | $241.39 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jul 24 | Solomon Moshkevich | Common Stock | Sell | Dispose S | No | Yes | 105.1597 | 549 | 57.73 k | 113,637 |
22 Jul 24 | John Fesko | Common Stock | Sell | Dispose S | No | Yes | 105.1592 | 549 | 57.73 k | 109,391 |
22 Jul 24 | Chapman Steven Leonard | Common Stock | Sell | Dispose S | No | Yes | 105.1591 | 2,638 | 277.41 k | 210,377 |
22 Jul 24 | Daniel Rabinowitz | Common Stock | Sell | Dispose S | No | Yes | 105.1587 | 815 | 85.70 k | 207,457 |
21 Jul 24 | Chapman Steven Leonard | Common Stock | Option exercise | Acquire M | No | No | 0 | 1,774 | 0.00 | 213,015 |
21 Jul 24 | Chapman Steven Leonard | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 1,774 | 0.00 | 3,550 |
21 Jul 24 | Sheena Jonathan | Common Stock | Option exercise | Acquire M | No | No | 0 | 143 | 0.00 | 302,141 |
21 Jul 24 | Sheena Jonathan | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 143 | 0.00 | 287 |
21 Jul 24 | Daniel Rabinowitz | Common Stock | Option exercise | Acquire M | No | No | 0 | 644 | 0.00 | 208,272 |
21 Jul 24 | Daniel Rabinowitz | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 644 | 0.00 | 1,288 |
News
(NTRA) - Analyzing Natera's Short Interest
23 Jul 24
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years
18 Jul 24
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today
4 Jul 24
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,400 Today
13 Jun 24
Amazon, Natera And A Financial Stock: CNBC's 'Final Trades'
11 Jun 24
Press releases
New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma
26 Jul 24
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
3 Jul 24
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
17 Jun 24
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
3 Jun 24
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
23 May 24